Enwei Pharmaceutical Co

Enwei Pharmaceutical Co Current Assets

The Current Assets of Enwei Pharmaceutical Co (301331.SZ) as of Oct 23, 2026 is 101.79 M CNY. In the previous year, Current Assets was 415.99 M CNY — a change of -75.53% (lower).

Current Assets

101.79 MCNY

YoY

-75.53%

Last updated:

Current Assets of Enwei Pharmaceutical Co is 2025 101.79 M CNY. Current Assets of Enwei Pharmaceutical Co was 2024 415.99 M CNY. It decreases by -75.53% lower compared to the previous year.

The Enwei Pharmaceutical Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
253.57 M CNY
Jan 1, 2020
330.38 M CNY
Jan 1, 2021
334.14 M CNY
Jan 1, 2022
354.29 M CNY
Jan 1, 2023
378.67 M CNY
Jan 1, 2024
415.99 M CNY
Jan 1, 2025
101.79 M CNY
The Enwei Pharmaceutical Co Current Assets history
YEARCurrent AssetsYoY
101.79 MCNY-75.53%
415.99 MCNY+9.86%
378.67 MCNY+6.88%
354.29 MCNY+6.03%
334.14 MCNY+1.14%
330.38 MCNY+30.29%
253.57 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

Current Assets of Enwei Pharmaceutical Co is 101.79 M CNY in 2025.

Current Assets of Enwei Pharmaceutical Co changed from 415.99 M CNY to 101.79 M CNY, representing a -75.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Enwei Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co